Comparisons

ALT and AST are both liver enzymes, but they have different tissue origins and clinical significance. Understanding the ALT/AST ratio helps distinguish liver damage from muscle damage.

Total testosterone measures all circulating testosterone, while free testosterone measures only the unbound, biologically active fraction. For TRT patients and bodybuilders, free testosterone is often the more clinically relevant marker.

Ferritin measures iron stores while soluble transferrin receptor (sTfR) reflects iron demand at the cellular level. Together they distinguish between true iron deficiency, functional deficiency, and inflammation-driven ferritin elevation.

Both markers track red blood cell status, but haemoglobin measures oxygen-carrying protein concentration while haematocrit measures the volume fraction of red cells. On TRT, haematocrit is used more often for clinical decisions, but haemoglobin is more physiologically meaningful.

Testosterone and DHT are both androgens, but they differ in potency, tissue selectivity, and clinical implications. Understanding the relationship between them is essential for managing TRT side effects.

HDL and LDL are both cholesterol-carrying lipoproteins, but they perform opposite functions in the body and carry opposite implications for cardiovascular risk. Anabolic steroids simultaneously suppress HDL and elevate LDL, creating a double hit that dramatically accelerates atherosclerosis.

Total cholesterol is the sum of all cholesterol fractions including the protective HDL. Non-HDL cholesterol subtracts HDL from total cholesterol to capture all atherogenic particles in a single number. Non-HDL is a more accurate cardiovascular risk predictor, particularly when triglycerides are elevated.

LH and FSH are both pituitary gonadotropins suppressed by AAS use, but they control different testicular functions and recover at different rates, making their distinction critical for PCT monitoring and fertility assessment.

Fasting glucose is a real-time snapshot of blood sugar, while HbA1c reflects your average glucose control over 2-3 months. For athletes using GH or peptides, both have strengths and blind spots.

RBC count measures the absolute number of red blood cells while haematocrit measures the proportion of blood volume they occupy. On cycle, these two markers can diverge in clinically meaningful ways: understanding each one separately prevents misinterpretation and guides better decisions about phlebotomy and hydration.

MCV measures the average size of red blood cells while RDW measures the variation in their size. On cycle, these two indices combine to reveal iron depletion before ferritin drops to classically deficient levels, with RDW rising first as an early warning signal before MCV begins to fall.

LDL cholesterol measures the cholesterol content carried by LDL particles, while ApoB counts the actual number of atherogenic particles. In steroid users, ApoB is often a more accurate risk predictor because LDL can underestimate particle count when particles are small and dense.

Testosterone enanthate and testosterone cypionate are the two most commonly prescribed testosterone esters for TRT and bodybuilding. Their differences are minimal, and they are clinically interchangeable for most purposes.

Testosterone enanthate and testosterone propionate sit at opposite ends of the short-to-long ester spectrum. Enanthate offers stable levels with infrequent injections, while propionate demands daily or every-other-day dosing in exchange for rapid onset, faster clearance, and tighter hormonal control.

Testosterone enanthate and testosterone undecanoate represent fundamentally different approaches to TRT. Enanthate requires weekly or twice-weekly injections with rapid onset, while undecanoate (Nebido/Aveed) offers injections every 10 to 14 weeks but comes with a prolonged, complex loading phase and less predictable blood levels.

Testosterone cypionate is a long-acting ester suited to TRT and consistent bulking protocols, while testosterone propionate is a short-acting ester that demands frequent injections but offers faster onset, faster clearance, and more agile dose control.

Testosterone cypionate and injectable testosterone undecanoate (Nebido/Aveed) are both TRT formulations, but cypionate offers weekly dosing with rapid titration, while undecanoate provides quarterly injections at the cost of a complex loading phase, limited dose flexibility, and difficult blood test interpretation.

Testosterone propionate and injectable testosterone undecanoate sit at opposite extremes of the ester spectrum. Propionate clears in days and demands daily injections, while undecanoate sustains levels for months with quarterly dosing. They are rarely compared clinically but represent the full range of injectable testosterone pharmacokinetics.

Clomiphene is a racemic mixture of two isomers with opposing effects, while enclomiphene is the pure active isomer. Enclomiphene provides equivalent LH/FSH stimulation with fewer estrogenic side effects, less SHBG elevation, and a cleaner side effect profile, making it the preferred choice when available.

HCG and enclomiphene are both used to preserve fertility and testicular function during TRT, but they work through completely different mechanisms. HCG bypasses the pituitary and acts directly on testicular Leydig cells. Enclomiphene works at the pituitary by blocking estrogen feedback, raising both endogenous LH and FSH.

HCG and gonadorelin both aim to maintain testicular function during TRT, but they act at different levels of the HPG axis. HCG acts directly on Leydig cells, bypassing the pituitary entirely. Gonadorelin acts on the pituitary as a GnRH analogue, stimulating endogenous LH and FSH release to maintain the complete downstream signalling cascade.

MK-677 (oral, 24-hour half-life, higher IGF-1 ceiling) vs ipamorelin (injectable, pulsatile, cleaner side-effect profile). The trade-off between convenience and metabolic safety.

MK-677 stimulates endogenous GH release (oral, lower ceiling, more insulin resistance per IU-equivalent). Exogenous GH bypasses the pituitary (injectable, no ceiling, dose-titratable, more expensive).

Both are 19-nor steroids with progestogenic activity, but they differ dramatically in potency, side effect profile, and monitoring requirements. Understanding these differences is essential for compound selection and bloodwork planning.

BPC-157 and TB-500 are the two most popular tissue-repair peptides in bodybuilding, but they work through different mechanisms. BPC-157 targets angiogenesis, collagen synthesis, and gut repair; TB-500 targets cell migration, anti-fibrotic remodelling, and systemic anti-inflammatory signalling. Most experienced users run them together.

Ipamorelin and CJC-1295 no-DAC work through different receptor classes and are typically stacked together, not chosen between. Ipamorelin is a GHRP (ghrelin receptor agonist) that triggers GH release; CJC-1295 no-DAC is a GHRH analog that primes and amplifies the pulse. Understanding the distinction helps users optimise their GH peptide protocol.

Sermorelin is a GHRH 1-29 analog (pituitary primer); ipamorelin is a selective GHRP (GH pulse trigger). Different receptor classes, different mechanisms, and different risk profiles. They are synergistic when stacked but serve distinct roles when used alone.

Anastrozole is a reversible non-steroidal aromatase inhibitor; exemestane is an irreversible steroidal inhibitor that permanently inactivates each enzyme molecule it binds. Both lower estradiol in men, but their mechanisms, half-lives, and rebound behaviour differ in ways that matter when dosing in a TRT or bodybuilding context.

Anavar (oxandrolone) is an oral 17-alpha-alkylated DHT derivative; primobolan (methenolone) is most commonly used as an injectable DHT family compound with no 17-alpha-alkylation. Primobolan is gentler on lipids, the liver, and the HPG axis at female doses. Anavar has the convenience of oral dosing and easier sourcing. Both carry virilization risk because both elevate androgen receptor activity in DHT-sensitive tissues.

Anavar (oxandrolone) and Winstrol (stanozolol) are both oral 17-alpha-alkylated DHT derivatives often grouped as 'women's' AAS. Winstrol is meaningfully worse than anavar on every clinically monitorable metric: deeper HDL crash, more virilization per mg, joint pain notorious for ending training cycles, and a worse-tasting recovery curve. The two are not interchangeable and the literature does not support running winstrol as a female alternative when anavar is available.

Retatrutide is a triple agonist (GLP-1, GIP, glucagon) producing 28.3 percent body weight loss at 12mg over 80 weeks (TRIUMPH-1). Tirzepatide is a dual agonist (GLP-1, GIP) producing 20.9 percent over 72 weeks (SURMOUNT-1). Retatrutide wins on weight loss and liver fat, tirzepatide wins on approval status and cardiovascular tolerability.

Retatrutide is a triple agonist (GLP-1, GIP, glucagon) producing 28.3 percent body weight loss at 12mg over 80 weeks. Semaglutide is the original GLP-1-only agonist producing 14.9 percent at 2.4mg over 68 weeks (STEP-1). Retatrutide nearly doubles the weight loss magnitude, but semaglutide is approved, accessible, and has years of real-world safety data.

CJC-1295 no-DAC (plus ipamorelin) produces discrete GH pulses 1 to 3 times per day, preserving insulin sensitivity between pulses. MK-677 produces sustained 24-hour GH elevation, raising IGF-1 by up to 100% but also raising fasting glucose 0.3 mmol/L and HbA1c 0.2% in a 2-year RCT. The choice depends on metabolic tolerance, cutting versus bulking goals, and injectable versus oral preference.

Both ipamorelin and hexarelin are GHRPs that produce potent GH release, but hexarelin non-selectively activates corticotrophs and other pituitary cell types, raising ACTH, cortisol, and prolactin at therapeutic doses. Ipamorelin was designed for pituitary somatotroph selectivity, producing GH release without cortisol or prolactin elevation even at 200 times the effective GH dose. This selectivity is why ipamorelin displaced hexarelin in performance use.

Both CJC-1295 no-DAC and tesamorelin are GHRH analogs that amplify pulsatile GH release. Tesamorelin is FDA-approved, backed by Phase 3 RCT data in 806 patients (Falutz 2010), showing 15.4% visceral fat reduction, 48 mg/dL triglyceride drop at 52 weeks, and a 7.2% cholesterol to HDL ratio improvement with no glucose change. CJC-1295 no-DAC is shorter-acting and typically requires ipamorelin co-injection for a complete pulse but costs substantially less. The choice depends primarily on evidence requirements, visceral fat reduction as a specific goal, and cost.

Tesamorelin and MK-677 both elevate GH and IGF-1 but through opposite mechanisms with opposite metabolic costs. Tesamorelin is FDA-approved, glucose-neutral over 52 weeks in 806 patients, and produces 15% visceral fat reduction. MK-677 is oral, cheap, and raises fasting glucose 26% in 4 weeks (Chapman 1996) with insulin resistance documented at 12 months (Nass 2008). For TRT users with metabolic syndrome, the choice is not close: tesamorelin is the right tool, MK-677 is the wrong one.

Tesamorelin and semaglutide both reduce visceral fat but through fundamentally different mechanisms with different lean mass tradeoffs. Tesamorelin drives GH-mediated lipolysis with lean mass preservation. Semaglutide drives caloric deficit with lean mass loss (8-11% in body composition substudies). They stack cleanly for TRT users with metabolic syndrome and stubborn VAT.

GLOW is GHK-Cu 50mg plus BPC-157 10mg plus TB-500 10mg (70mg total, 5:1:1 ratio). KLOW adds KPV 10mg, a tripeptide studied in inflammatory bowel disease. Both deliver 316mcg of elemental copper per 2mg GHK-Cu dose. No human RCT validates either blend.

MOTS-C (AMPK activator, improves insulin sensitivity, mostly animal evidence) vs MK-677 (GH secretagogue, worsens insulin sensitivity, strong human RCT data). The two push HOMA-IR in opposite directions, which is exactly why athletes ask about pairing them.

5-amino-1MQ (oral NNMT inhibitor, raises NAD+ in fat tissue, preclinical only) vs MOTS-C (injectable mitochondrial peptide, activates AMPK in muscle, early human data). Both end up boosting NAD+ and SIRT1, but by opposite routes and in different organs, and neither has a completed fat-loss trial in humans.

SS-31 protects cardiolipin and reduces oxidative stress (no blood marker confirms it). MOTS-C activates AMPK and targets glucose and insulin sensitivity (trackable on a metabolic panel). They are marketed as a pair but solve completely different problems.

IGF-1 LR3 (injected IGF-1, no pituitary brake, acute hypoglycaemia risk) vs MK-677 (oral ghrelin mimetic that raises IGF-1 slowly through your own GH, with documented glucose creep). Same end-marker, opposite safety profiles.